An interventional study of Pterygium excision and Intraoperative mitomycin C in Recurrent Pterygium, sponsored by Sun Yat-sen University. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-07-09.
Sponsored by Sun Yat-sen University · Not applicable, Interventional, and Treatment
The purpose of this randomized clinical trial is to compare the efficacy and safety of intraoperative mitomycin C(MMC) combined with limbal conjunctival autograft(LCAG) or conjunctival autograft(CAG) for recurrent pterygium surgery. The investigators will also evaluate particular risk factors related to pterygium recurrence
Intraoperative mitomycin C after pterygium excision is widely used to prevent recurrce of recurrent pterygium. Conjunctival autograft with or without limbal tissue used to cover the bare sclera will efficiently reduce postoperative longstanding epithelial defect.
Patients with recurrent pterygium will be randomly assigned to undertake pterygium excision followed by intraoperative mitomycin C with conjunctival autograft or limbal conjunctival autograft .The patients will be followed at least 12 months. Corneal recurrence is considered as a fibrovascular ingrowth beyond the limbus with conjunctival drag in the area of previous pterygium excision.
109 studies on the registry are indexed under Pterygium; 9 are open to participants now.
This study's planned enrollment of 116 is above the median of 60 across 93 interventional studies indexed under Pterygium.
Browse Pterygium studies →Sun Yat-sen University is the lead sponsor of 1,690 studies on the registry; 619 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
After pterygium excision, intraoperative mitomycin c (0.02%) for 5 minutes will be applied topically onto the exposed surgical area and then conjunctival autograft without limbal tissue will be used to cover the bare sclera.
Procedure: Pterygium excision · Procedure: Intraoperative mitomycin C · Procedure: Conjunctival autograft
After pterygium excision, intraoperative mitomycin c (0.02%) for 5 minutes will be applied topically onto the exposed surgical area and then limbal conjunctival autograft will be used to cover the bare sclera.
Procedure: Pterygium excision · Procedure: Intraoperative mitomycin C · Procedure: Limbal conjunctival autograft
Partial conjunctiva and anterior tenon's membrane underneath will be removed after the excision of pterygium tissue.
Intraoperative mitomycin C (0.02%) will be applied for 5 minutes after pterygium excision.
Also known as: MMC
A conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.
Also known as: CAG
A limbal conjunctival autograft will be applied to cover the conjunctival defect after pterygium excision.
Also known as: LCAG
Recurrence of pterygium
Time frame: One year
Visual acuity
Time frame: One year
Healing time of corneal epithelium
Time frame: Four weeks
Healing time of conjunctival epithelium
Time frame: Four weeks
Postoperative complications
Time frame: One year
This study is status unknown, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.